Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved TOVIAZ opvejer risiciene ved behandling af de symptomer (øget vandladningshyppighed og/ eller - trang og/ eller urgeinkontinens), som kan forekomme hos patienter med overaktiv blæresyndrom.
The Committee for Medicinal Products for Human Use (CHMP) decided that TOVIAZ’ s benefits are greater than its risks for the treatment of the symptoms (increased urinary frequency and/ or urgency and/ or urgency incontinence) that may occur in patients with overactive bladder syndrome.